ROLE OF EARLY ETIOLOGICAL DECODING OF ACUTE RESPIRATORY VIRAL INFECTIONS IN ANTIVIRAL THERAPY CHOICE FOR CHILDREN IN A HOSPITAL SETTING

2020 ◽  
Vol 99 (1) ◽  
pp. 100-106 ◽  
Author(s):  
V.N. Timchenko ◽  
◽  
V.F. Sukhovetskaya ◽  
T.M. Chernova ◽  
E.V. Barakina ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Viral Infections ◽  
Hospital Setting ◽  
Therapy Choice ◽  
Respiratory Viral Infections

scholarly journals Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections

2018 ◽  
Vol 99 (2) ◽  
pp. 215-223 ◽  
Author(s):  
E P Tikhonova ◽  
T Yu Kuz'mina ◽  
N V Andronova ◽  
O A Tyushevskaya ◽  
T A Elistratova ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Clinical Efficacy ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Antiviral Drug ◽  
Antiviral Drugs ◽  
Control Group ◽  
Efficacy And Safety ◽  
Respiratory Viral Infections ◽  
Adaptive Reactions

Aim. Comparative study of clinical efficacy and safety of antiviral drug triazavirin and umifenovir in the treatment of patients with acute respiratory viral infections and influenza. Methods. The study included 100 patients aged 18 to 65 years diagnosed with moderate acute respiratory viral infection. Group 1 included 34 patients receiving umifenovir 200 mg 4 times a day for 5 days, and comparison group included 32 patients who received triazavirin 1 capsule (250 mg) 3 times a day for 5 days. Group 3 (control group) included 34 patients not treated with antiviral therapy. Efficacy and safety of the studied antiviral drugs were evaluated based on clinical symptoms in the disease course and were confirmed by adaptive reactions of the organism. Results. Among patients receiving triazavirin, recovery time and fever, headache and catarrhal syndrome resolution time were less than among patients who received umifenovir. On triazavirin treatment with favorable tolerability, symptomatic medications (antipyretics) were discontinued, and the duration of their use was less, than in patients receiving umifenovir. Evaluation of clinical efficacy of umifenovir and triazavirin for the treatment of acute respiratory viral infections and influenza demonstrated that the drugs effectively reverse the main symptoms of the disease (p <0.05), reduce complications incidence (18.1±2.1% vs. 55.9±3.2%, p <0.05) and contribute to the stabilization of adaptive reactions of the organism in contrast to the results of patients not receiving etiotropic therapy (6.9±2.9% vs. 12.8±2.7, p <0.05). During the use of umifenovir by day 4 and during the use of triazavirin by day 3 intoxication and catarrhal syndromes had been reversed, while in case of the absence of antiviral therapy, 55.8% of patients had continuing intoxication and catarrhal symptoms. Conclusion. The results of the study allow defining umifenovir and triazavirin as the first line of defense against acute respiratory viral infections with good efficacy and tolerability of the drugs.

scholarly journals ARVI antiviral therapy in children in modern clinical practice

2019 ◽  
pp. 183-187 ◽  
Author(s):  
E. A. Dondurey ◽  
E. V. Obraztsova ◽  
Yu. S. Semiletko ◽  
N. V. Ovchinnikova ◽  
E. G. Golovacheva ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Antiviral Therapy ◽  
Viral Infections ◽  
Case Histories ◽  
Prescribe Antibiotic ◽  
Continuous Evaluation ◽  
Wide Range ◽  
Respiratory Viral Infections ◽  
High Level ◽  
Favorable Safety

In the context of the wide range of products recommended for antiviral therapy, there is still a need for continuous evaluation of their effectiveness and safety in pediatrics. The work describes the experience of non-interventional study of the domestic drug umifenovir in the modern clinical practice. The authors studied 216 case histories of children hospitalized with acute respiratory viral infections at early stages of the disease. Against the background of the drug administration a significant reduction in the duration of all symptoms of the infectious process and the need to prescribe antibiotic therapy to patients, a reduction in the chances of complicated flu and acute respiratory viral infections, as well as a favorable safety spectrum and a high level of compliance during treatment.

scholarly journals A Role of the Nervous System in Modulating Respiratory Viral Infections

2021 ◽  
Author(s):  
A.E. Mcgovern ◽  
N. Verzele ◽  
B. Chua ◽  
C. Law ◽  
M. Ritchie ◽  
...  
Keyword(s):  
Nervous System ◽  
Viral Infections ◽  
Respiratory Viral Infections

scholarly journals THE ROLE OF RESPIRATORY VIRAL INFECTIONS AMONG CHILDREN HOSPITALIZED FOR COMMUNITY-ACQUIRED PNEUMONIA IN A DEVELOPING COUNTRY

2008 ◽  
Vol 27 (10) ◽  
pp. 939-941 ◽  
Author(s):  
Cristiana M. Nascimento-Carvalho ◽  
Catarina T. Ribeiro ◽  
Maria Regina A. Cardoso ◽  
Aldina Barral ◽  
César A. Araújo-Neto ◽  
...  
Keyword(s):  
Developing Country ◽  
Viral Infections ◽  
Community Acquired Pneumonia ◽  
Respiratory Viral Infections

scholarly journals Role of ILC2 in Viral-Induced Lung Pathogenesis

2021 ◽  
Vol 12 ◽  
Author(s):  
Wendy Fonseca ◽  
Nicholas W. Lukacs ◽  
Srikanth Elesela ◽  
Carrie-Anne Malinczak
Keyword(s):  
Viral Infections ◽  
Treatment Options ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Structural Repair ◽  
Respiratory Viral Infections ◽  
Lung Pathogenesis ◽  
Syncytial Virus

Innate lymphoid type-2 cells (ILC2) are a population of innate cells of lymphoid origin that are known to drive strong Type 2 immunity. ILC2 play a key role in lung homeostasis, repair/remodeling of lung structures following injury, and initiation of inflammation as well as more complex roles during the immune response, including the transition from innate to adaptive immunity. Remarkably, dysregulation of this single population has been linked with chronic lung pathologies, including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrotic diseases (IPF). Furthermore, ILC2 have been shown to increase following early-life respiratory viral infections, such as respiratory syncytial virus (RSV) and rhinovirus (RV), that may lead to long-term alterations of the lung environment. The detrimental roles of increased ILC2 following these infections may include pathogenic chronic inflammation and/or alterations of the structural, repair, and even developmental processes of the lung. Respiratory viral infections in older adults and patients with established chronic pulmonary diseases often lead to exacerbated responses, likely due to previous exposures that leave the lung in a dysregulated functional and structural state. This review will focus on the role of ILC2 during respiratory viral exposures and their effects on the induction and regulation of lung pathogenesis. We aim to provide insight into ILC2-driven mechanisms that may enhance lung-associated diseases throughout life. Understanding these mechanisms will help identify better treatment options to limit not only viral infection severity but also protect against the development and/or exacerbation of other lung pathologies linked to severe respiratory viral infections.

scholarly journals Possible role of vitamin D supplementation in coronavirus disease 2019

2020 ◽  
Vol 6 (9) ◽  
pp. 376
Author(s):  
Devi Dayal
Keyword(s):  
Vitamin D ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Winter Season ◽  
Vitamin D Supplementation ◽  
Vitamin D Status ◽  
Vitamin D Levels ◽  
Respiratory Viral Infections ◽  
The Impact

<p>Vitamin D deficiency (VDD) is presumed to play a role in several infective and non-infective conditions such as acute respiratory infections, tuberculosis, diabetes, hypertension, stroke etc. Most of the respiratory viral infections occur during winter season when the vitamin D levels in most individuals are generally low. The current pandemic of coronavirus disease 2019 (COVID-19) which began during winter season similar to the previous epidemics due to coronaviruses, has again stirred a debate on the role of VDD in the initiation and spread of the pandemic. The data on vitamin D status in patients with COVID-19 is however lacking. Different vitamin D supplementation strategies have recently been suggested as part of several countermeasures aimed at reducing the impact of COVID-19 pandemic. This brief narrative review discusses the evidence for the link between VDD and COVID-19 and the approaches suggested for vitamin D supplementation.</p>

Sign in / Sign up

Export Citation Format

Share Document